Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Inclusion Criteria: * Participants who are naïve to chemotherapy for multiple myeloma and not eligible for autologous stem cell transplantation * Participants with symptomatic multiple myeloma: a) Intramedullary monoclonal plasma cells greater than or equal to (\>=) 10% or histologically confirmed plasmacytoma; b) Presence of monoclonal protein in the serum or urine; c) Myeloma-related organ impairment as defined in protocol * Participants with presence of an illness that is detectable by definitions as defined in protocol * Postmenopausal, sterilized or sexually inactive women, including women of childbearing potential who exercise effective contraceptive measures before and during the clinical trial Exclusion Criteria: * Participants with previous experience of receiving a therapy for multiple myeloma (excluding radiotherapy and dexamethasone \< 160mg in total) * Participants with severe peripheral neuropathy (Grade \>= 2 by NCI CTC version 4.0) * Pregnant or breastfeeding mothers * Participants with mental illness that can interfere with his/her cooperation with the therapy or the monitoring conditions of the clinical trial * Participants with other serious medical conditions (such as uncontrolled hypertension, diabetes mellitus and active infections)